Submit Manuscript now
Impact Factor 2.6

admin

Tracheoesophageal Fistula in Chemo-Radio Treated Mediastinal Bulky Non-Hodgkin Lymphoma

Leave a Comment / Issue 2 Articles, Volume 3 / By

In this case report, we describe the clinical history of a 67-year-old male with a mediastinal bulky non-Hodgkin lymphoma, treated with chemotherapy (R-CHOP scheme) and radiotherapy. Less than six months after complete remission, he was referred to our Gastroenterology Unit with gradual onset esophageal dysphagia, pyrosis and dry cough, especially evident after eating. The symptoms …

Tracheoesophageal Fistula in Chemo-Radio Treated Mediastinal Bulky Non-Hodgkin Lymphoma Read More »

Generic Sofosbuvir-Declatasvir for Hepatitis C patients in Qatar: A Real-Life Observational Study

Leave a Comment / Issue 2 Articles, Volume 3 / By

The hepatitis C virus (HCV) has been considered one of the most pathogens currently challenging the medical community worldwide. Due to the development of new Direct Acting Anti-viral (DAAs, it is expected that almost all patients with HCV infection will achieve a Sustained Viral Response (SVR) in the near future. However, DAA treatment is expensive …

Generic Sofosbuvir-Declatasvir for Hepatitis C patients in Qatar: A Real-Life Observational Study Read More »

Endoscopic Ultrasonography of Malignant Rectal Tumors for the Decision-Making of Therapeutic Action

Leave a Comment / Issue 2 Articles, Volume 3 / By

In Cuba rectal tumor occupies the fourteenth cause of death among malignant and fifth tumors among malignant digestive tumors and its proper management depends on its staging. At present, endoscopic ultrasonography as a very well defined diagnostic value in the preoperative staging of rectal cancer, its introduction increases the ability to delimit the rectal wall …

Endoscopic Ultrasonography of Malignant Rectal Tumors for the Decision-Making of Therapeutic Action Read More »

Gastric Inflammatory Fibroid Polyp-Like Lesion with Specific Morphology during Proton Pump Inhibitor Treatment

Leave a Comment / Issue 1 Articles, Volume 3 / By

The patient was a 75-year-old woman who achieved Helicobacter pylori eradication. She started proton pump inhibitor (PPI) therapy for reflux esophagitis in 2016. Gastrointestinal endoscopy two years later (in 2018) revealed yellow sub mucosal tumor-like polypoid lesions in the greater curvature in the upper part of the gastric corpus and anterior wall

Seasonal Patterns of Acute Esophageal Variceal Bleeding In Patients with Liver Cirrhosis

Leave a Comment / Issue 1 Articles, Volume 3 / By

Seasonal variations in the incidence of esophageal variceal bleeding in patients with end stage liver disease have been explored in various studies but the results were inconsistent. In the present retrospective analysis, consecutive patients with liver cirrhosis admitted with esophageal variceal bleeding to the Galilee medical center from 2010 until 2015 were evaluated

Excision of a Giant Huge Idiopathic Pseudo-Pancreatic Cyst: A Case Report

Leave a Comment / Issue 1 Articles, Volume 3 / By

A pseudo-pancreatic cyst is a common clinical entity characterized by a fibrous tissue wall which is devoid of epithelium with localized fluid rich in pancreatic enzymes as amylase [1]. Its incidence reaches 30-40% after pancreatitis [1, 2], decompression is indicated when symptomatic cysts persist for more than six weeks and for those larger than six …

Excision of a Giant Huge Idiopathic Pseudo-Pancreatic Cyst: A Case Report Read More »

The Chronic Hepatitis B Treatment Virologic Response to HAART among HBV/ HIV Co-Infected Patients Who Failed Lamivudine Containing Regimens

Leave a Comment / Issue 1 Articles, Volume 3 / By

All HIV/HBV co-infected patients in Serbia have been treated with HAART containing an anti- HBV drug, irrespective of CD4 cell count and HBV disease status in order to prevent more active liver disease. Like in many developing countries, lamivudine containing HAART was used in all HBV/HIV co-infected individuals

What Our Author Say's

I am glad that I found this platform. It was easy to get my research published and I was guided at every step. I highly recommend them.
Shuang-Qin Yi
am grateful to the Japanese Journal of Gastroenterology and Hepatology for helping me with my research and publishing it. Looking forward to more work with them.
Makki Fayadh
It has been a pleasure working with the Japanese Journal of Gastroenterology and Hepatology. They have been amazing in helping me with my manuscript
Han Min
I am glad that I submitted my manuscript here. They helped me make necessary edits and published the best version of it. I highly recommend them.
Sadaf Saleem

FAQ's About Jajgastrohepto

The Japanese Journal of Gastroenterology and Hepatology accepts all kinds of manuscripts, such as research, studies, reviews, clinical images, editorials, commentaries, etc.

For Detailed quotations reach out submission@jajogh.jp

It depends on the length of the manuscript and the reviews and edits needed.

We will help you with as many reviews and edits as are required to make your manuscript perfect for publication.

A good impact factor for JJGH is 2.0 as per Journal Citations Reports of 2021.

Niigata, 7F Stork Building Kagamibashi, 1230-7, 7-bancho, Kamiookawamaedori, Chuo-ku, Niigata, 951-8068, Japan.

*2021 Journal unofficial Impact Factor was established by dividing the number of articles published in 2020 with the number of times they are cited in 2021 based on Google Scholar Citation Index database. If ‘X’ is the total number of articles published in 2020 and ‘Y’ is the number of times these articles were cited in indexed journals during 2021 then, journal impact factor = Y/X.

Copyright 2018-2024 All Rights Reserved.